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Endothelin-1 is a small vasoconstrictor peptide that was first identified in 1988. Here we review the evidence implicating ET-1 in
tumorigenesis. In particular, we concentrate on the role of ET-1 in mitogenesis, apoptosis, angiogenesis, tumour invasion and
metastasis, and discuss the potential for endothelin-system modulation as an adjuvant therapeutic strategy.
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The potent vasoconstrictor peptide endothelin-1 (ET-1) was first
isolated from the culture media of porcine endothelial cells in 1988
(Yanagisawa et al, 1988). It is one of a family of multifunctional
peptides (ET-1, 2 and 3) that are closely related to the sarafotoxins
derived from the venom of the burrowing asp. Of these isoforms,
ET-1 has been the most extensively studied to date, and has been
implicated in cancer.
ET-1 is synthesised via proteolytic cleavage of a large precursor
molecule, pre-pro ET-1, which is facilitated by the metalloprotei-
nase, endothelin converting enzyme (ECE). This pathway is
summarised in Figure 1. The endothelins exert their physiological
effect via two receptors, ETA and ETB, which are G-protein-coupled
transmembrane receptors found in both vascular and nonvascular
tissues. Ligand-receptor binding induces dissociation of the
receptor-linked G-protein subunits, which may then associate
with multiple intracellular effectors. The ETA receptor has varying
affinities for the endothelin isoforms (ET-14ET-24ET-3),
whereas the ETB receptor shows no selective affinity for any of
the ET subtypes (Sakamoto et al, 1991).
The endothelins have been implicated in numerous physiologi-
cal and pathological conditions, including hypertension, cardiac
failure and disseminated intravascular coagulation. Interest in the
role of ET-1 in cancer has grown over the last decade, following the
work of Kusuhara et al (1990) that demonstrated ET-1 production
by several tumour cell lines. Currently there is evidence that ET-1
may modulate mitogenesis, apoptosis, angiogenesis, tumour
invasion and development of metastases. The aim of this article
is to review the role of ET-1 in cancer and possible ET-system
modulation as an adjuvant therapeutic strategy.
ENDOTHELIN EXPRESSION IN CANCER
Elevated plasma levels of ET-1 have been detected in patients with
various solid tumours, including hepatocellular, gastric and
prostate cancer (Nakamuta et al, 1993; Nelson et al, 1995,
Ferrari-Bravo et al, 2000), where levels are greatest in patients
with metastastic, hormone refractory disease.
Our group has demonstrated elevated plasma levels of ET-1 in
patients with primary colorectal cancer, with and without liver
metastases (Shankar et al, 1998), compared with healthy controls.
Plasma levels of Big ET-1 have also been found to be significantly
raised in colorectal cancer patients compared with age- and sex-
matched controls (Simpson et al, 2000). Of note, this study also
found that both preoperative and intraoperative portal plasma
levels were significantly higher in Dukes’ D carcinomas compared
with localised or regional disease.
Many human cancer cell lines have been shown to synthesise
ET-1 in vitro, including colonic, breast, stomach, prostate and
glioblastoma cells (Kusuhara et al, 1990; Ali et al, 2000b). This is
also reflected in vivo, where increased tissue immunoreactivity for
ET-1 has been demonstrated in numerous cancer types, including
ovarian, hepatocellular and breast tumours (Bagnato et al, 1999;
Yamashita et al, 1991; Suzuki et al, 1998). We have reported
increased immunopositivity for ET-1 in colorectal cancer sections.
Of note, no correlation was noted between intensity of staining and
Dukes’ staging (Asham et al, 2001).
Furthermore, changes in the expression of endothelin system
components have also been demonstrated in premalignant tissues.
Egidy et al (2000) demonstrated, using reverse transcriptase
polymerase chain reaction (RT–PCR), increased expression of
pre-pro ET-1 and ECE mRNA in colorectal adenomas compared
with normal colon. Also, Alanen et al (2000) demonstrated that
immunoreactivity for ET-1 in breast ductal carcinoma in situ
(DCIS) specimens was significantly higher (Po0.005) than that in
normal breast tissue. A further significant increase in immuno-
reactivity was found in invasive tumours compared with DCIS
(Po0.02). These results suggest that modulation of the endothelin
system may be an early phenomenon in tumorigenesis.
ENDOTHELIN RECEPTORS AND CANCER
Increased ETA receptor expression in malignant tissue has been
demonstrated using immunohistochemistry and/or autoradiogra-
phy in several cancer types including colorectal, ovarian and
prostate tumours (Nelson et al, 1996; Bagnato et al, 1999; Ali et al,
2000a). In the latter, levels of receptor expression have been found Received 7 October 2002; accepted 8 November 2002
*Correspondence: to: Dr M Loizidou, Department of Surgery, Royal Free
and University College London Medical School, Charles Bell House, 67-
73 Riding House Street, London, W1W 7EJ, UK;
E-mail: m.loizidou@ucl.ac.uk
British Journal of Cancer (2003) 88, 163–166
& 2003 Cancer Research UK All rights reserved 0007– 0920/03 $25.00
www.bjcancer.comto correlate with both Gleason score and presence of metastases
(Gohji et al, 2001).
Of note, in normal tissue from these sites the ETB receptor
predominates, whereas the ETA receptor becomes prevalent in
both primary tumours and metastases. Interestingly, relative
hypermethylation of the ETB gene has been demonstrated in
several prostate, bladder and colon cancer cell lines. Furthermore,
this has also been found to correlate with transcriptional down-
regulation (Pao et al, 2001), providing a plausible mechanism for
reduced ETB receptor expression in malignant tissue.
ENDOTHELIN AS A MITOGEN
ET-1 has been shown to stimulate the growth of several human
cancer cell lines in vitro including colorectal, ovarian, prostate,
Kaposi’s sarcoma and melanoma cells (Yohn et al, 1994; Nelson
et al, 1996; Bagnato et al, 1999; Ali et al, 2000b; Bagnato et al,
2001). Several groups have demonstrated that in epithelial tumours
in vitro, this mitogenic effect is mediated via the ETA receptor
(Nelson et al, 1996; Bagnato et al, 1999; Ali et al, 2000b).
The growth of nonepithelial tumours does not appear to be ETA
dependent. Studies on human melanoma cells have shown that the
mitogenic effect of ET-1 is purely ETB receptor dependent (Kikuchi
et al, 1996), whereas antagonism of either receptor partially
inhibits in vitro growth of Kaposi’s sarcoma cells (Bagnato et al,
2001). This has also been demonstrated in vivo, where the specific
ETB antagonist (BQ788) was shown to significantly slow melanoma
tumour growth in nude mice (Lahav et al, 1999).
The role of ET-1 as an autocrine growth factor has been
demonstrated in human ovarian and colon cancer cell lines
(Bagnato et al, 1995; Ali et al, 2000a). Furthermore, Moraitis et al
(1999) have implicated ET-1 as a paracrine growth factor in
ovarian cancer. They demonstrated that ET-1 production by
human ovarian cancer cells stimulated the growth of carcinoma-
associated fibroblasts in coculture, an effect that was partially
inhibited by both ETA and ETB antagonism. However, a recent
study by Kernochan et al (2002) found that ET-1 has no effect on
human colonic subepithelial myofibroblast proliferation, although
contraction and migration of these cells was stimulated through ET
receptor-mediated myosin phosphorylation. The effects of ET-1 on
proliferation and other cellular processes in cancer are sum-
marised in Figure 2.
ENDOTHELIN AND APOPTOSIS
In addition to its mitogenic effect, there is evidence that ET-1 may
also contribute to tumour growth by protecting cells from
apoptosis. ET-1 has been shown to protect rat fibroblasts and
human endothelial cells (Wu-Wong et al, 1997) from serum-
deprivation-induced apoptosis in vitro (Shichiri et al, 1997).
Peduto-Eberl et al (2000) have also more recently demonstrated
that ET-1 is a survival factor for rat colon carcinoma cells against
FasL-mediated apoptosis. From these data, it could be suggested
that ET-1 may influence tumour growth by influencing both
cellular proliferation and cell death.
ENDOTHELIN AND ANGIOGENESIS
Endothelin-1 may also facilitate tumour growth through the
promotion of angiogenesis. ET-1 is a potent mitogen for both
endothelial cells and vascular smooth muscle cells (VSMC) in vitro
(Komuro et al, 1988; Pedram et al, 1997). In addition, ET-1 may
indirectly enhance endothelial cell proliferation through stimula-
tion of vascular endothelial growth factor (VEGF) production by
other cell types (Pedram et al, 1997; Salani et al, 2000a). The
reverse situation has also been demonstrated in endothelial cells,
where VEGF has been shown to enhance ET-1 mRNA expression
and ET-1 secretion (Matsuura et al, 1998).
Furthermore, ET-1 potentiates the effect of several proangio-
genic factors in vitro, including PDGF and VEGF (Pedram et al,
1997; Yang et al, 1999). ET-1 also stimulates invasion and
morphological differentiation of human umbilical vein endothelial
cells (HUVEC) in matrigel in vitro, and this may be facilitated via
ET-1-induced production of matrix metalloproteinase-2 (MMP-2)
by endothelial cells (Salani et al, 2000b).
In vivo, when combined with VEGF, ET-1 has been shown to
stimulate angiogenesis in subcutaneously implanted matrigel plugs
in mice (Salani et al, 2000b). Bek and McMillen (2000)
demonstrated that ET-1 also stimulated angiogenesis in a rat
corneal model with a similar efficacy to VEGF. In this model they
found that ET-1-stimulated angiogenesis was inhibited by either
ETA antagonism, or mixed antagonism with bosentan, but was not
affected by the addition of an ETB antagonist. These data suggest
that ET-1 may be an important modulator of angiogenesis in
cancer.
ENDOTHELIN-1 AND TUMOUR
PROGRESSION/METASTASES
There is increasing evidence that ET-1 may also influence tumour
invasion and metastases. A recent study in human ovarian
carcinoma cell lines has demonstrated that ET-1 can regulate the
expression of several MMPs, in particular, MMP-2 and MMP-9,
and can downregulate tissue inhibitors of matrix metalloprotei-
nases (TIMP) 1 and 2 (Rosano et al, 2001).
ET-1 may also modulate the growth of bony metastases from
prostate cancer. In human prostate cancer cells, ET-1 production is
enhanced by bone contact, which in turn blocks osteoclastic bone
reabsorption (Chiao et al, 2000). This is also reflected in vivo,
where Nelson et al (1999) used an osteoblastic tumour model
(WISH–a human tumour derived from amnion) to demonstrate
Pre-pro ET-1 (212AAs) 
Pro ET-1
Big ET-1 (38 AAs)
Endothelin converting enzyme
Endothelin-1 (21 AAs)
Figure 1 Biosynthesis of ET-1. The signal peptide (grey box) is cleaved
from the amino terminus of the 212 amino-acid precursor molecule to
generate pre-pro ET-1. Further cleavage, via furin-like endopeptidases
including endothelin-converting enzyme (ECE), results in the generation of
mature ET-1.
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Figure 2 Actions of endothelin-1 in cancer.
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cantly more bone growth in nude mice compared with vector only
controls.
Furthermore, our group has demonstrated increased immuno-
reactivity for ET-1 in endothelial cells within colorectal liver
metastases compared with surrounding vessels (Shankar et al,
1998), suggesting that ET-1 may be involved in modulation of
tumour blood flow, known to be altered in liver metastases.
ENDOTHELIN ANTAGONISM AS A THERAPEUTIC
STRATEGY
Several in vivo models have been used to assess the role of
endothelin antagonism in tumorigenesis. Work originating from
our department using intraportally injected syngeneic MC28 cells
in rats demonstrated that ETA antagonism with BQ123 signifi-
cantly reduced hepatic tumour load compared with controls
(Asham et al, 2001).
Peduto-Eberl et al (2000) assessed the effect of bosentan, a dual
receptor antagonist, on the growth of peritoneal tumours derived
from a syngeneic rat colonic adenocarcinoma cell line. Although
bosentan was not able to control tumour progression, they did find
that tumours were generally of lower grade, and there were fewer
spontaneous deaths in the treated vs the untreated groups. Egidy
et al (2000) used the same tumour model to assess histological
differences between tumours of bosentan-treated animals and
controls. They demonstrated that tumour cells were less densely
packed, and there was less collagen matrix around tumour nodules
in the treated compared to the untreated group.
Finally, using an osteoblastic tumour model in nude mice
Nelson et al (1999) have shown that ETA antagonism with A127722
significantly reduced the growth of new bone compared with
vehicle treated controls. Although in vivo results have so far not
yielded dramatic results, they are encouraging and warrant further
investigation.
Recently, a phase I trial of the ETA receptor antagonist
atrasentan was undertaken in 31 patients with refractory
adenocarcinomas (Carducci et al, 2002). Nearly half of the patients
had prostate cancer (n¼14), although patients with other
malignancies, including colorectal (n¼6), breast (n¼2), lung
(n¼4) and renal cell carcinoma (n¼3), were recruited. Side
effects relating to the physiological consequences of ETA blockade
include headache, hypotension and peripheral oedema that were
generally tolerated, being mild to moderate in nature. Of the 24
patients who completed the initial 28-day trial, no complete or
partial radiological responses were observed. However, a third of
patients with tumour-related pain experienced alleviation of
symptoms. Additionally, prostatic specific antigen (PSA) levels
were found to fall in half of the prostate cancer patients, and
reduction in other biochemical tumour markers such as CEA and
CA125 were also recorded, suggesting antitumour activity. It
remains to be seen whether this will result in a significant clinical
benefit.
CONCLUSION
Components of the endothelin system are altered in cancer, and
appear to aid tumour growth and progression in a number of
epithelial cancer types, via direct and indirect mechanisms. From
the evidence to date, it appears that selective ETA antagonism
provides the most likely effective method of endothelin system
inhibition in cancer. With generally mild to moderate side effects,
and suggested antitumour activity, further development and
clinical evaluation of these agents is warranted to determine
possible therapeutic potential as an adjuvant anticancer strategy.
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